Poster-Disease-modifying Therapy
October 25, 2021
Clinical Outcomes in Patients with COVID-19 Infection during Phase IV Studies of Cladribine Tablets for Treatment of Multiple Sclerosis
Background: The COVID-19 pandemic has become a significant concern for patients with multiple sclerosis (MS) and their healthcare...
Poster-Disease-modifying Therapy
October 25, 2021
Updated Post-Approval Safety of Cladribine Tablets in the Treatment of Multiple Sclerosis, with Particular Reference to Respiratory Viral Infections and COVID-19
Background: Several integrated analyses have reported on the safety of cladribine tablets 10 mg (3.5 mg/kg cumulative dose over 2 years...
Poster-Disease-modifying Therapy
October 25, 2021
Characterization of Peripheral Immune Cell Dynamics and Repopulation Patterns in the First 12 Months of Cladribine Tablets Treatment: Magnify-MS Study
Background: The action of cladribine tablets (CladT) on immune cells may be key for both onset and durability of its effect in people with...